Viking Therapeutics, Inc.
VKTX
$23.94
$0.341.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.75% | 33.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.49% | 7.35% | |||
| Operating Income | -26.49% | -7.35% | |||
| Income Before Tax | -42.01% | -12.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -42.01% | -12.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.01% | -12.09% | |||
| EBIT | -26.49% | -7.35% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -41.44% | -11.56% | |||
| Normalized Basic EPS | -40.79% | -12.06% | |||
| EPS Diluted | -41.44% | -11.56% | |||
| Normalized Diluted EPS | -40.79% | -12.06% | |||
| Average Basic Shares Outstanding | 0.39% | 0.47% | |||
| Average Diluted Shares Outstanding | 0.39% | 0.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||